ADC cytotoxicity: How to provide operator safety

Antibody‑drug conjugates (ADCs) have become a key treatment option in oncology, merging the targeted specificity of antibodies with highly potent cytotoxic payloads. While their therapeutic potential is remarkable, this same potency poses substantial risks for operators during manufacturing. Even minimal exposure to the ADC cytotoxicity can lead to serious health issues, making it crucial to implement strict handling protocols. 

Throughout the production of ADCs, cytotoxicity remains a pervasive risk during upstream processing, conjugation, fill‑finish, and packaging operations. Facilities must safeguard operators, maintain product integrity, and prevent environmental contamination.

So, what is the best solution to ensure ADC safety in cGMP-compliant manufacturing? 

What makes an antibody-drug conjugate so toxic? 

A scientific look at ADC cytotoxicity 

ADC toxicity originates from the cytotoxic payloads attached to the antibody molecule. These payloads – such as auristatins, maytansinoids, or DNA‑damaging agents – are engineered to kill cancer cells at extremely low concentrations. Unlike biologics such as monoclonal antibodies, ADC payloads are classified as high‑potency active pharmaceutical ingredients (HPAPIs). 

More about ADC technology

How can ADCs pose a threat to operator safety? 

Even exposure at nanogram‑level can be harmful to human cells, as many ADC payloads interfere with DNA replication or microtubule formation. Long-term exposure may elevate the risk of cancer, while aerosols, droplets, surface contamination, or bag breakages can lead to immediate safety hazards in the workplace. [[1]] 

Before the production begins, the potential hazard risk in ADC handling is assessed by the occupational exposure limits (OELs). Each ADC compound is assigned to an OEL value which determines the necessary safety measures for maintaining a controlled ADC manufacturing environment. [[2]] 

Safe ADC facilities

Facility safety risks in ADC manufacturing

Facilities handling ADCs must manage compounds whose payloads are highly potent and active at extremely low volumes, which drives the need for consistently enclosed, tightly controlled processing environments. Hazard and exposure assessments establish very low OELs for payloads and often for the conjugated molecule, meaning facility design must prevent airborne release and cross‑contamination. This includes controlled pressure regimes, segregated zones, and validated cleaning and containment procedures, ensuring that operations with elevated exposure potential are executed in a manner that minimizes aerosolization and prevents migration into adjacent areas. The overall objective is a facility and process architecture that reliably supports closed, leak‑free product handling across all process steps. [[2]] 

Operator safety risks in ADC manufacturing

Because ADC payloads have extremely low allowable exposure levels, even small quantities can present meaningful risk. Exposure can occur via inhalation or surface contamination, especially during tasks with higher dispersion potential, such as:

• Conjugation and buffer exchange may involve manual sampling or open manipulations that can generate contamination.
• Filling and aliquoting require particular attention, since even if Annex 1 does not mandate isolators for every setup, aseptic and closed filling remains essential to prevent aerosol formation and accidental release.
• Single-use bag handling introduces breakage risks, especially when bags are frozen or exposed to mechanical stress. Therefore, secondary containment is recommended to prevent product loss and operator exposure.
• Dispensing and weighing of HPAPI powder pose an immediate exposure risk when performed without a closed, automated transfer route.
• Transfer between unit operations increases contamination and safety risks when bulk drug substances are moved without protected, closed pathways.

Together, these challenges highlight the importance of closed and reliable secondary‑protection systems.

Reducing product loss and contamination risk 

For ADCs, preventing product loss is directly tied to reducing operator exposure. Robust secondary containment strategies that mitigate bag breakage or leakage support enhanced operational excellence and promote a safer environment when handling materials associated with high acute toxicity.

Single Use Support’s RoSS® shell provides robust secondary containment for all available single‑use bags, protecting frozen ADC solutions and enabling safe handling, storage, and shipping of bulk drug substances. Bottle RoSS protects bottles and connected tubing assemblies, reduces product loss during cold chain handling, and supports the safe movement of HPAPI‑containing fluid paths. 

Together, these systems establish a critical physical barrier that reduces operator exposure while maintaining batch integrity. 

FAQ